跳至主要内容
临床试验/NCT06086132
NCT06086132招募中不适用

Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry (ISACS CARDIONCO-PREDICT)

University of Bologna5 个研究点 分布在 3 个国家目标入组 10,000 人开始时间: 2025年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
10,000
试验地点
5
主要终点
All causes mortality

研究概览

简要总结

This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 years old or older
  • Capable of giving informed consent
  • Diagnosis of cancer scheduled for treatment according to treating physician's discretion
  • Life expectancy >1 year
  • For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs

排除标准

  • Age <18 years old
  • Not able to give informed consent
  • Life expectancy <1 year
  • Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's

结局指标

主要结局

All causes mortality

时间窗: For approximately a median of 3 years

Occurrence of all cause death

Cardiovascular mortality

时间窗: For approximately a median of 3 years

Occurrence of cardiovascular mortality

Cancer therapy-related cardiovascular toxicity

时间窗: For approximately a median of 3 years

Occurrence of cancer therapy-related cardiovascular toxicity

次要结局

未报告次要终点

研究者

发起方
University of Bologna
申办方类型
Other
责任方
Principal Investigator
主要研究者

Olivia Manfrini, MD

Professor

University of Bologna

研究点 (5)

Loading locations...

相似试验